Timothy A Yap, MD, PhD on AVID200: Is This Practice Changing? @MDAndersonNews

Timothy A Yap, MD, PhD on AVID200: Is This Practice Changing? @MDAndersonNews

User Photo
Cancer-News

1 month
8 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Timothy A Yap, MD, PhD of MD Anderson Cancer Center @MDAndersonNews discusses AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.

Read here: https://meetinglibrary.asco.org/record/187808/abstract

Up Next Autoplay